Cargando…
Side-effects of cidofovir in the treatment of recurrent respiratory papillomatosis
Recurrent respiratory papillomatosis (RRP) is a chronic and difficult to treat disease of the larynx. In 1998, the first article was published that described the use of the antiviral substance cidofovir to treat this disease. Although the results are promising, there remains some concern about the p...
Autores principales: | Broekema, Ferdinand I., Dikkers, Frederik G. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Springer-Verlag
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2441494/ https://www.ncbi.nlm.nih.gov/pubmed/18458927 http://dx.doi.org/10.1007/s00405-008-0658-0 |
Ejemplares similares
-
Recurrent respiratory papillomatosis: the role of cidofovir
por: Tran, Mai Ngoc, et al.
Publicado: (2018) -
Effectiveness of cidofovir intralesional treatment in recurrent respiratory papillomatosis
por: Wierzbicka, Małgorzata, et al.
Publicado: (2011) -
Efficacy of cidofovir in recurrent juvenile respiratory papillomatosis
por: Valera, Fabiana, et al.
Publicado: (2015) -
Treatment of recurrent respiratory papillomatosis and adverse reactions following off-label use of cidofovir (Vistide(®))
por: Tjon Pian Gi, Robin E. A., et al.
Publicado: (2011) -
Recurrent respiratory papillomatosis by HPV: review
of the literature and update on the use of cidofovir
por: FUSCONI, M., et al.
Publicado: (2014)